<DOC>
	<DOCNO>NCT01425112</DOCNO>
	<brief_summary>Bevacizumab anti vascular endothelial growth factor ( anti-VEGF ) substance know reduce neovascularization fibrovascular proliferation inflammatory condition , include post-operative inflammation . It show efficacy numerous ocular condition ( off-label ) , include Age related macular degeneration , proliferative diabetic retinopathy , neovascular glaucoma corneal neovascularization . It explore option prevent recurrence pterygium adjunct improve outcomes trabeculectomy . There debate mode duration bevacizumab administration trabeculectomy . This study aim compare single subconjunctival dose bevacizumab topical therapy one month term outcomes trabeculectomy surgery , non-progression field loss stable intraocular pressure ( IOP ) control .</brief_summary>
	<brief_title>Comparison Subconjuctival Versus Topical Bevacizumab Adjunct Therapy Trabeculectomy</brief_title>
	<detailed_description />
	<mesh_term>Disease Progression</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Primary Open Angle Glaucoma Progression Failure reach target IOP Non compliant Resurgery Systemic contraindication bevacizumab All form glaucoma</criteria>
	<gender>All</gender>
	<minimum_age>42 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>trabeculectomy</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>anti-VEGF</keyword>
	<keyword>Efficacy</keyword>
</DOC>